Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

461. Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy

Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy "Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute E" by Amy M. Hernandez < > > > > > Title Author Date of Graduation Fall 10-18-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Patients with chronic obstructive pulmonary disease (COPD) experience progressive pulmonary decline (...) with each acute exacerbation of disease. Current therapy is focused on treating acute symptoms of COPD, but there are no medications that have been implemented to delay the progression of the disease. Herbal therapies have been developed by researchers to supplement baseline therapy for COPD with the goal of prolonging healthful pulmonary states, thereby slowing disease progression. Methods: Exhaustive search of available medical literature from Medline, CINAHL, Web of Science, EBMR and NIH websites

2013 Pacific University EBM Capstone Project

462. Helping older people with very severe chronic obstructive pulmonary disease (COPD) towards the end of their lives: a systematic review of holistic interventions

Helping older people with very severe chronic obstructive pulmonary disease (COPD) towards the end of their lives: a systematic review of holistic interventions Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2013 PROSPERO

463. The link Between COPD and smoking: a systematic review and meta analysis

The link Between COPD and smoking: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2013 PROSPERO

464. Effect of an interprofessional rehabilitation program on daily physical activity in a primary care setting for patients with less advanced COPD: a systematic review

Effect of an interprofessional rehabilitation program on daily physical activity in a primary care setting for patients with less advanced COPD: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2013 PROSPERO

465. Towards effective self-management interventions for patients with heart failure or COPD: an individual patient data (IPD) meta-analysis

Towards effective self-management interventions for patients with heart failure or COPD: an individual patient data (IPD) meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2013 PROSPERO

466. Which interventions are effective for improving physical activity levels in people with COPD? A review protocol

Which interventions are effective for improving physical activity levels in people with COPD? A review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2013 PROSPERO

467. What is the relationship of anxiety and depression to exacerbations of COPD and the resultant hospital admissions and readmissions and are there any other mediating factors involved?

What is the relationship of anxiety and depression to exacerbations of COPD and the resultant hospital admissions and readmissions and are there any other mediating factors involved? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2013 PROSPERO

468. Non invasive positive versus external negative pressure ventilation and continuous airway pressure in COPD patients

Non invasive positive versus external negative pressure ventilation and continuous airway pressure in COPD patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2013 PROSPERO

469. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium (QVA149) for the treatment of COPD

Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium (QVA149) for the treatment of COPD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2013 PROSPERO

470. Acupuncture for the treatment of chronic pulmonary obstruction disease (COPD): a systematic review of randomized clinical trials

Acupuncture for the treatment of chronic pulmonary obstruction disease (COPD): a systematic review of randomized clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2013 PROSPERO

471. Anoro Ellipta (umeclidinium and vilanterol inhalation powder) - For the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Anoro Ellipta (umeclidinium and vilanterol inhalation powder) - For the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Ellipta (umeclidinium /vilanterol) Powder for Inhalation Company: GlaxoSmithKline Application No.: 203975 Approval Date: 12/18/2013 Persons

2013 FDA - Drug Approval Package

472. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) - For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Ellipta (fluticasone furoate and vilanterol trifenatate) Inhalation Powder Company: GlaxoSmithKline

2013 FDA - Drug Approval Package

473. [Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "COPD"]

[Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "COPD"] Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für das DMP chronisch obstruktive Lungenerkrankung [Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "COPD"] Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für das DMP chronisch (...) obstruktive Lungenerkrankung [Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "COPD"] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für das DMP chronisch obstruktive

2013 Health Technology Assessment (HTA) Database.

474. Action Plans for Individuals with Chronic Obstructive Pulmonary Disease (COPD): A Rapid Review

Action Plans for Individuals with Chronic Obstructive Pulmonary Disease (COPD): A Rapid Review Action plans for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Action plans for individuals with chronic obstructive pulmonary disease (COPD): a rapid review McCurdy BR Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation McCurdy BR. Action plans for individuals with chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2013 Authors' conclusions Based on 1 systematic review that evaluated the effectiveness of action plans with or without limited education (education sessions up to 1 hour in length) compared with usual care, the following conclusions were reached: - Action plans significantly increase antibiotic and corticosteroid use during an acute

2013 Health Technology Assessment (HTA) Database.

475. Tiotropium Respimat Inhaler and the Risk of Death in COPD. (PubMed)

Tiotropium Respimat Inhaler and the Risk of Death in COPD. Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.In (...) this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 μg or 5 μg, as compared with tiotropium HandiHaler at a once-daily dose of 18 μg. Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 μg or 2.5 μg vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 μg vs. HandiHaler). We also assessed

2013 NEJM Controlled trial quality: predicted high

476. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

477. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study (PubMed)

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study The efficacy and safety of two doses of aclidinium bromide were evaluated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). In this 24-week, double-blind trial, patients were randomised to twice-daily aclidinium (200 μg or 400 μg) or placebo. The primary efficacy end-point was change in trough forced expiratory volume in 1 s (FEV(1)) at week 24. Other end-points included peak (...) placebo in baseline-adjusted mean SGRQ total score (-3.8 and -4.6 units; p<0.001 and p<0.0001) and TDI focal score (0.6 and 1.0 units; p<0.05 and p<0.001) at week 24. With both aclidinium doses, the incidence of anticholinergic adverse events was low, and similar to placebo. Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD.

Full Text available with Trip Pro

2012 EvidenceUpdates Controlled trial quality: predicted high

478. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review

Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

479. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis Thabane M, COPD Working Group Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Thabane M, COPD Working Group. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(4). 2012 Authors' objectives The objective of this evidence-based analysis was to determine the effectiveness and cost-effectiveness of smoking cessation interventions in the management of chronic obstructive pulmonary disease (COPD). Authors' conclusions

2012 Health Technology Assessment (HTA) Database.

480. Community-based multidisciplinary care for patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Community-based multidisciplinary care for patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis Community-based multidisciplinary care for patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis Community-based multidisciplinary care for patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis Sikich N Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sikich N. Community-based multidisciplinary care for patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(5). 2012 Authors' objectives The objective of this evidence-based analysis was to determine the effectiveness and cost-effectiveness of multidisciplinary care (MDC) compared

2012 Health Technology Assessment (HTA) Database.